Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewMNI caged kainic acid
说明： Caged kainic acid
化学名： (2S,3S,4S)-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid 4-methoxy-7-nitro-1H-indolinyl amide
纯度： ≥99% (HPLC)
生物活性 for MNI caged kainic acid
Kainic acid (Cat.No. 0222) caged with the photosensitive 4-methoxy-7-nitroindolinyl group. Generates large inward currents at resting membrane potential upon wide field photolysis in Purkinje neurons. Selectively photoactivates kainate receptors when used in conjunction with an AMPA antagonist, such as GYKI 53655 (Cat.No. 2555). Suitable for uncaging with 300-380 nm excitation. Exhibits rapid uncaging rate relative to ionotropic glutamate receptor activation. Also suitable for two-photon uncaging experiments at 720 nm.
许可信息
Sold under licence from the Medical Research Council
技术数据 for MNI caged kainic acid
| 分子量 | 389.4 |
| 公式 | C19H23N3O6 |
| 储存 | Store at -20°C |
| 纯度 | ≥99% (HPLC) |
| CAS Number | 1315378-75-6 |
| PubChem ID | 57414719 |
| InChI Key | IQGCUMUIYXHZOT-AHIWAGSCSA-N |
| Smiles | C=[C@@](C)[C@@H]1[C@H](CC(N2C(C([N+]([O-])=O)=CC=C3OC)=C3CC2)=O)[C@@H]([C@](O)=O)NC1 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for MNI caged kainic acid
参考文献 for MNI caged kainic acid
参考文献是支持产品生物活性的出版物。
Maier et al (2005) Comparative analysis of inhibitor effects of caged ligands for the NMDA receptor. J.Neurosci.Meths. 142 1 PMID: 15652611
Palma-Cerda et al (2013) New caged neurotransmitter analogues based on methoxy-nitroindole and nitrophenylethoxycarbonyl caging groups are selective for glutamate receptor subtypes. Neuropharmacology 63 624 PMID: 22609535
Palma-Cerda et al (2012) New caged neurotransmitter analogs selective for glutamate receptor sub-types based on methoxynitroindoline and nitrophenylethoxycarbonyl caging groups. Neuropharmacology. 63 624 PMID: 22609535
Passlick and Ellis-Davies et al (2017) Comparative one- and two-photon uncaging of MNI-glutamate and MNI-kainate on hippocampal CA1 neurons. J.Neurosci.Methods. PMID: 29051090
关键词: MNI caged kainic acid, MNI caged kainic acid supplier, MNI, caged, compounds, kainic, acid, 4-methoxy-7-nitroindolinyl, photosensitive, neurotoxin, iGluR, ionotropic, glutamate, kainate, receptors, agonists, Caged, Glutamate, Compounds, Kainate, Receptors, 2225, Tocris Bioscience
1 篇 MNI caged kainic acid 的引用文献
引用文献是使用了 Tocris 产品的出版物。 MNI caged kainic acid 的部分引用包括：
Passlick and Ellis-Davies (2017) Comparative one- and two-photon uncaging of MNI-glutamate and MNI-kainate on hippocampal CA1 neurons. J.Neurosci.Methods. 293 321 PMID: 29051090
MNI caged kainic acid 的评论
目前没有该产品的评论。 Be the first to review MNI caged kainic acid and earn rewards!
Have you used MNI caged kainic acid?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.